Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Glioblastoma 3Oligodendroglioma 2Astrocytoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Proliferative Breast Disease 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Optic Nerve Glioma 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gliosarcoma 1Glioma 1Ependymoma 1Childhood Brain Neoplasm 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Asymptomatic 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Dynamic Contrast Enhanced Magnetic Resonance Imaging × Clear all
NCT01931709 2023-11-18

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

University of Washington

Phase NA Terminated
35 enrolled 11 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡